Elevated lactate dehydrogenase Significance in Polycythemia Vera
An elevated lactate dehydrogenase (LDH) in polycythemia vera (PV) generally indicates increased cellular turnover and tissue stress from an active myeloproliferative clone.
In PV, a persistently elevated LDH (especially when confirmed on repeat testing) functions as a clinical indicator of possible progression to post-PV myelofibrosis rather than a PV-specific response marker.
Clinical Interpretation and Diagnostic Implications
LDH above the upper limit of normal is included among minor diagnostic criteria for myelofibrosis, which supports the interpretation of LDH elevation as a potential progression signal when seen alongside other evolving features.
Post-PV myelofibrosis should be suspected when LDH elevation is accompanied by any combination of worsening anemia, rising leukocyte abnormalities, progressive splenomegaly, leukoerythroblastosis, or new constitutional symptoms.
Management Strategy for Elevated LDH in PV
LDH elevation should trigger evaluation for disease progression rather than changes based on LDH alone.
The evaluation should include repeat LDH with concurrent complete blood count (CBC) trend review, peripheral blood smear assessment for leukoerythroblastosis, targeted symptom assessment, and physical examination for splenomegaly.
Further diagnostic assessment for progression (including bone marrow evaluation) is appropriate when LDH remains elevated and progressive clinical or hematologic abnormalities are present.
PV Core Treatment to Reduce Complications
PV should be treated with phlebotomy to maintain hematocrit below 45% for thrombosis-risk reduction.
PV should be treated with low-dose aspirin unless contraindicated.
Risk-adapted cytoreductive therapy is appropriate when there is high-risk PV or when disease control is inadequate or progression features develop.
Medication Selection Algorithm for Cytoreductive Therapy
Cytoreductive therapy selection should be based on risk category, prior therapy tolerance, blood count trajectory, and comorbidities.
Common cytoreductive options include:
- Hydroxyurea (first-line cytoreductive therapy for many high-risk patients) [2]
- Interferon-based therapy (including pegylated interferon) [2]
- Ruxolitinib (for hydroxyurea-resistant or hydroxyurea-intolerant PV) [2]
Initiation Thresholds and Indications That Should Raise the Level of Concern
Cytoreductive therapy should be initiated in PV when at least one cytoreduction criterion is present, including extreme thrombocytosis, progressive or persistent leukocytosis, symptomatic or progressive splenomegaly, or persistently high symptom burden.
Persistent leukocytosis is defined in the ELN 2021 recommendations as greater than 15 × 10^9/L, and additional definitions for progression depend on baseline values.
A persistently inadequate hematocrit target requiring repeated phlebotomy should prompt cytoreductive escalation.
Common Pitfalls to Avoid
LDH should not be treated as a stand-alone PV response measure because LDH elevation is used more broadly as a progression-associated marker in myelofibrosis criteria.
LDH should not be interpreted without concurrent CBC trends and clinical progression assessment, since progression to post-PV myelofibrosis requires integration of hematologic and clinical changes.
Targets and Goals of Therapy in PV With Suspected Progression
The hematocrit target in PV is below 45% with phlebotomy.
The overarching goals include prevention of thrombotic and hemorrhagic complications and prevention or early detection of hematologic progression.
In the presence of suspected progression to myelofibrosis, treatment planning should be aligned to the progression phenotype and diagnostic confirmation rather than continued PV-only management.